Citigroup Inc Design Therapeutics, Inc. Transaction History

Citigroup Inc

$150 Billion
Q1 2024

A detailed history of Citigroup Inc transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 6,329 shares of DSGN stock, worth $21,202. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,329

Previous 4,815 31.44%

Holding current value

$21,202

Previous $12,000 108.33%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$2.27 - $4.03 $3,436 - $6,101	1,514 Added 31.44%	6,329 $25,000
Q4 2023 Feb 09, 2024	BUY	$1.99 - $2.76 $8,041 - $11,153	4,041 Added 522.09%	4,815 $12,000
Q3 2023 Nov 09, 2023	SELL	$2.05 - $8.14 $20,381 - $80,927	-9,942 Reduced 92.78%	774 $1,000
Q2 2023 Aug 10, 2023	BUY	$4.99 - $7.64 $36,471 - $55,840	7,309 Added 214.53%	10,716 $67,000
Q1 2023 May 11, 2023	SELL	$5.5 - $9.77 $584,391 - $1.04 Million	-106,253 Reduced 96.89%	3,407 $19,000

Q4 2022 Feb 09, 2023	BUY	$7.86 - $17.2 $592,588 - $1.3 Million	75,393 Added 220.02%	109,660 $1.13 Million
Q3 2022 Nov 10, 2022	BUY	$14.09 - $25.57 $362,859 - $658,504	25,753 Added 302.48%	34,267 $573,000
Q2 2022 Aug 10, 2022	SELL	$9.91 - $17.33 $101,161 - $176,904	-10,208 Reduced 54.52%	8,514 $119,000
Q1 2022 May 12, 2022	SELL	$11.17 - $20.89 $105,858 - $197,974	-9,477 Reduced 33.61%	18,722 $302,000
Q4 2021 Feb 10, 2022	BUY	$13.64 - $21.41 $46,253 - $72,601	3,391 Added 13.67%	28,199 $604,000
Q3 2021 Nov 10, 2021	BUY	$13.99 - $20.03 $347,063 - $496,904	24,808 New	24,808 $364,000

Others Institutions Holding DSGN

# of Institutions

Shares Held

30.5M

Call Options Held

100

Put Options Held

100

View Full List

About Design Therapeutics, Inc.

Ticker DSGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,807,900
Market Cap $187M
Description
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...

More about DSGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account